GSK to acquire clinical-stage biopharma company Affinivax
The $3.3 billion deal will strengthen GSK’s vaccine pipeline.
GSK has entered into a definitive agreement to acquire Affinivax, a clinical-stage biopharmaceutical company based in Boston, Massachusetts, for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones.
GSK, which is the world's largest vaccine maker by sales, says this will bolster its vaccine pipeline.
Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines which target diseases such as pneumonia, meningitis and sinusitis.
Despite the current availability of pneumococcal vaccines, there remains a significant unmet medical need in this area. This is because the number of serotypes in current vaccines is limited due to the degree of immunological interference observed when using existing conjugation technologies.
To address this, Affinivax has developed its Multiple Antigen Presenting System (MAPS), a novel technology that supports higher valency than conventional conjugation technologies. This enables broader coverage against prevalent pneumococcal serotypes and potentially creates higher immunogenicity than current vaccines.
Affinivax’s most advanced vaccine candidate (AFX3772) is expected to enter Phase III clinical trials shortly.
Speaking about the news, Dr Hal Barron, Chief Scientific Officer at GSK, said: ‘The proposed acquisition further strengthens our vaccines R&D pipeline, provides access to a new, potentially disruptive technology, and broadens GSK’s existing scientific footprint in the Boston area.’
Steven Brugger, CEO of Affinivax, said he was ‘proud that GSK has recognized our team’s accomplishments’ and added that GSK is ‘an ideal new home for our MAPS platform and the team behind its success’.
GSK also reiterated its outlook for 2022 and its medium-term targets.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance